AR127247A1 - Inhibidores de cdk2 de ciclopentilpirazol - Google Patents

Inhibidores de cdk2 de ciclopentilpirazol

Info

Publication number
AR127247A1
AR127247A1 ARP220102682A ARP220102682A AR127247A1 AR 127247 A1 AR127247 A1 AR 127247A1 AR P220102682 A ARP220102682 A AR P220102682A AR P220102682 A ARP220102682 A AR P220102682A AR 127247 A1 AR127247 A1 AR 127247A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
subject
pharmaceutical composition
cdk2
acceptable salt
Prior art date
Application number
ARP220102682A
Other languages
English (en)
Inventor
Jessica Marie Grandner
Kevin M Johnson
Steven Magnuson
Jeremy Mark Murray
Brendan T Parr
Vishal A Verma
Yong Wang
Mingshuo Zeng
Melissa A Ashley
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR127247A1 publication Critical patent/AR127247A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se describen compuestos de fórmula (1) y sales farmacéuticamente aceptables de estos, composiciones farmacéuticas que los comprenden, y sus usos y preparación. Reivindicación 70: Una composición farmacéutica que comprende un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 69, o una sal farmacéuticamente aceptable de este, y un excipiente farmacéuticamente aceptable. Reivindicación 71: Un método para tratar un trastorno mediado por CDK2 en un sujeto que lo necesita, en donde el método comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 69, o una sal farmacéuticamente aceptable de este, o una composición farmacéutica de acuerdo con la reivindicación 70. Reivindicación 74: Un método para elaborar un medicamento para tratar un trastorno mediado por CDK2 en un sujeto que lo necesita, caracterizado porque se usa el compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 69, o una sal farmacéuticamente aceptable de este, o una composición farmacéutica de acuerdo con la reivindicación 70.
ARP220102682A 2021-10-05 2022-10-04 Inhibidores de cdk2 de ciclopentilpirazol AR127247A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163252394P 2021-10-05 2021-10-05

Publications (1)

Publication Number Publication Date
AR127247A1 true AR127247A1 (es) 2024-01-03

Family

ID=84245758

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102682A AR127247A1 (es) 2021-10-05 2022-10-04 Inhibidores de cdk2 de ciclopentilpirazol

Country Status (7)

Country Link
KR (1) KR20240077491A (es)
CN (1) CN118019734A (es)
AR (1) AR127247A1 (es)
AU (1) AU2022360968A1 (es)
CA (1) CA3229067A1 (es)
TW (1) TW202330501A (es)
WO (1) WO2023060057A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023208143A1 (zh) * 2022-04-28 2023-11-02 正大天晴药业集团股份有限公司 一种吡唑取代环戊酯衍生物及其用途
WO2024104455A1 (zh) * 2022-11-17 2024-05-23 山东绿叶制药有限公司 Cdk2抑制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20210065A7 (es) * 2019-01-31 2022-04-07 Pfizer Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria en cdk2
CN110536068B (zh) 2019-09-29 2021-09-28 Oppo广东移动通信有限公司 对焦方法和装置、电子设备、计算机可读存储介质
TW202246255A (zh) * 2021-02-12 2022-12-01 美商傳達治療有限公司 Ｃｄｋ抑制劑及其使用方法

Also Published As

Publication number Publication date
WO2023060057A1 (en) 2023-04-13
KR20240077491A (ko) 2024-05-31
AU2022360968A1 (en) 2024-02-29
CN118019734A (zh) 2024-05-10
TW202330501A (zh) 2023-08-01
CA3229067A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
CO2023000199A2 (es) Péptidos funcionalizados como agentes antivirales
AR127247A1 (es) Inhibidores de cdk2 de ciclopentilpirazol
CL2023001476A1 (es) Nuevos agentes antivirales derivados de la espiropirrolidina
BR112022025037A2 (pt) Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus
CO2023002852A2 (es) Péptidos funcionalizados como agentes antivirales
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
CO2024001367A2 (es) Compuestos antivirales
CL2023000881A1 (es) Compuestos y su uso en el tratamiento del cáncer
CO2021014210A2 (es) Compuestos de pirrol
ECSP23095674A (es) Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn)
AR124449A1 (es) Inhibidores de sos1 y usos de los mismos
AR127501A1 (es) Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
DOP2023000060A (es) Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención
AR111464A1 (es) Terapia combinada para el tratamiento de infecciones virales
DOP2021000254A (es) Compuestos de pirrolidina
AR125798A1 (es) Degradadores cdk2 y usos de los mismos
CO4130200A1 (es) Inhibidores de proteasa del hiv utiles en el tratamiento del sida
ECSP23054131A (es) Cocristal de un inhibidor de cdk
AR128257A1 (es) Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting
AR127561A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
CO2021017202A2 (es) Compuestos tricíclicos
BR112022016124A2 (pt) Composto de di-hidronaftiridinona, e método de preparação para este e uso médico deste
AR126482A1 (es) Agentes antivirales derivados de espiropirrolidina
AR126835A1 (es) Análogos deuterados y derivados de 4-bromo-2,5-dimetoxifenetilamina y usos de estos